These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25761233)

  • 1. The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
    Corneli AL; McKenna K; Perry B; Ahmed K; Agot K; Malamatsho F; Skhosana J; Odhiambo J; Van Damme L
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):578-84. PubMed ID: 25761233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.
    Corneli A; Perry B; McKenna K; Agot K; Ahmed K; Taylor J; Malamatsho F; Odhiambo J; Skhosana J; Van Damme L
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):452-61. PubMed ID: 26536315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa.
    Corneli AL; McKenna K; Headley J; Ahmed K; Odhiambo J; Skhosana J; Wang M; Agot K;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19152. PubMed ID: 25224613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
    Gilmore HJ; Liu A; Koester KA; Amico KR; McMahan V; Goicochea P; Vargas L; Lubensky D; Buchbinder S; Grant R
    AIDS Patient Care STDS; 2013 Oct; 27(10):560-6. PubMed ID: 24093809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
    Agot K; Taylor D; Corneli AL; Wang M; Ambia J; Kashuba AD; Parker C; Lemons A; Malahleha M; Lombaard J; Van Damme L
    AIDS Behav; 2015 May; 19(5):743-51. PubMed ID: 25100053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
    Haberer JE; Baeten JM; Campbell J; Wangisi J; Katabira E; Ronald A; Tumwesigye E; Psaros C; Safren SA; Ware NC; Thomas KK; Donnell D; Krows M; Kidoguchi L; Celum C; Bangsberg DR
    PLoS Med; 2013; 10(9):e1001511. PubMed ID: 24058300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
    Corneli A; Wang M; Agot K; Ahmed K; Lombaard J; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):555-63. PubMed ID: 25393942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antiretroviral chemoprophylaxis: current status.
    Baeten J; Celum C
    Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.
    Kintu A; Hankinson SE; Balasubramanian R; Ertel K; Tumwesigye E; Bangsberg DR; Haberer JE;
    J Acquir Immune Defic Syndr; 2015 May; 69(1):36-43. PubMed ID: 25942457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
    AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of emtricitabine-tenofovir in HIV PrEP.
    Kruse L; Stover K; Henderson H
    HIV Clin; 2014; 26(1):1, 4-7. PubMed ID: 24855688
    [No Abstract]   [Full Text] [Related]  

  • 19. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial.
    Corneli A; Perry B; Agot K; Ahmed K; Malamatsho F; Van Damme L
    PLoS One; 2015; 10(4):e0125458. PubMed ID: 25867624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.
    Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G; Corneli A
    Cult Health Sex; 2016 Sep; 18(9):1081-91. PubMed ID: 27093238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.